A Single-Arm, Exploratory, Self-Controlled Clinical Study of Hetrombopag for Secondary Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma

This study is a single-arm, exploratory, self-controlled clinical trial for the prevention of thrombocytopenia induced by gemcitabine plus cisplatin in the treatment of nasopharyngeal carcinoma. It aims to investigate the efficacy and safety of hetrombopag for the secondary prevention of thrombocytopenia caused by gemcitabine plus cisplatin in patients with nasopharyngeal carcinoma. The study protocol has been reviewed and approved by the Institutional Ethics Committee of Fujian Cancer Hospital, allowing the conduct of this clinical study.

Start Date30 Nov 2025

Sponsor / Collaborator

Fujian Cancer Hospital

NCT07243418

/ Not yet recruitingPhase 2IIT

Dual-cohort, Single-arm, Exploratory Phase II Clinical Study of Hetrombopag for Primary/Secondary Prevention of Thrombocytopenia Induced by ADC Drugs in Breast Cancer

The title of this study is: A two-cohort, single-arm, exploratory Phase II clinical study on the primary/secondary prevention ADC drug of heltrombopag for thrombocytopenia caused by breast cancer. This study is a two-cohort, single-arm, open-label, exploratory clinical trial for the prevention of thrombocytopenia caused by ADC drug treatment for breast cancer. This research was supported by Fujian Cancer Hospital. The protocol has been reviewed by the Ethics Committee of Fujian Cancer Hospital, which has agreed to conduct this clinical study.

Start Date30 Nov 2025

Sponsor / Collaborator

Fujian Cancer Hospital

ChiCTR2500111291

/ Not yet recruitingPhase 4IIT

Single arm, prospective clinical study on the application of Haiqupopa ethanolamine tablets in the treatment of thrombocytopenia (CTIT) caused by tumor therapy

Start Date15 Nov 2025

Sponsor / Collaborator

Henan Cancer Hospital

100 Clinical Results associated with Herombopag Olamine

100 Translational Medicine associated with Herombopag Olamine

100 Patents (Medical) associated with Herombopag Olamine

Literatures (Medical) associated with Herombopag Olamine

31 Dec 2025·Hematology

Adding recombinant human thrombopoietin to cyclosporine A and hetrombopag enhances the early hematologic response in transfusion-dependent non-severe aplastic anemia: a retrospective study

Article

Author: Shen, Shupei ; Yang, Chen ; Chen, Miao ; Liu, Ziwei ; Han, Bing ; Lin, Xijuan

OBJECTIVES:

Transfusion-dependent non-severe aplastic anemia (TD-NSAA) is a bone marrow failure disorder with high progression risk and transfusion complications, necessitating rapidly effective therapies. Recombinant human thrombopoietin (rhTPO) stimulates megakaryocyte proliferation through a mechanism distinct from that of oral TPO receptor agonists (TPO-RAs), suggesting a potential synergistic effect in accelerating hematopoietic recovery. This study evaluated the efficacy and safety of rhTPO plus cyclosporine A (CsA) and hetrombopag in patients with TD-NSAA.

METHODS:

In this retrospective study, data were collected from patients with newly diagnosed TD-NSAA treated with CsA + hetrombopag + rhTPO or CsA + hetrombopag alone between July 2022 and December 2023 at our center.

RESULTS:

Twenty-nine patients in the rhTPO group and 28 in the control group were enrolled. The overall response rates (ORRs) at 1 and 2 months were significantly higher in the rhTPO group (34.5% vs 10.7%, P = 0.033; 55.2% vs 28.6%, P = 0.042, respectively). Time to achieve OR was shorter (P = 0.035), and platelet transfusion independence rates at 2 and 3 months were higher in the rhTPO group (52.6% vs. 18.8%, P = 0.039; 63.2% vs. 25.0%, P = 0.024, respectively). No significant difference was observed between the two groups in 3/6 months ORRs or complete response rates. Adverse events were comparable between groups.

CONCLUSION:

Adding rhTPO to CsA + hetrombopag improves platelet recovery and early hematologic responses, supporting its potential role in optimizing the initial management of patients with TD-NSAA.

01 Nov 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Mechanism-based perspective on metal ion-induced signal instability and development of a robust LC-MS/MS method for trace quantification of hetrombopag in plasma

Article

Author: Chen, Jiao ; Wang, Jie ; Dai, Biying ; Wang, Xiaoli ; Han, Jiangbin ; Wu, Yuyu ; Lu, Huiyue ; Zhai, Lijuan ; Qian, Wen

Hetrombopag (Hengqu®) is an oral nonpeptide thrombopoietin receptor agonist for the treatment of thrombocytopenia and aplastic anemia. Research on the pharmacokinetic behavior is very important, but accurate quantification of metal-sensitive hetrombopag in biological specimens is a challenging analytical problem. In view of the presence of trace metals from a variety of sources, such as chromatographic system, containers, and the mass spectrometry spray needle, which can contribute to poor peak shape, tailing, and diminished recovery of compound. To ameliorate these problems, different solvent additives, mobile phase, containers and precipitant reagents were investigated to reduce the negative effects. In the present study, a robust, selective, and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of hetrombopag in dog plasma was developed based on the dual strategies: (1) 6 % perchloric acid in acetonitrile eliminates metal ion adsorption in storage containers, and (2) 0.01 % trifluoroacetic acid (TFA) in the mobile phase suppresses chelation in chromatographic systems. These two solvents are essential requirements for ensuring stable analytical signals. This method employed an InfinityLab Poroshell 120 EC-C18 column (4.6 ×50 mm, 2.7 μm, Agilent) with a gradient system comprising 0.01 % trifluoroacetic acid with 10 mM ammonium formate (phase A) and a mixture of H₂O: methanol: isopropanol (1:10:10, v/v/v) containing 0.01 % trifluoroacetic acid and 10 mM ammonium formate (phase B). The column temperature of 50℃ and the addition of isopropanol were beneficial for the separation of interfering peaks and target analyte peaks in plasma. The method exhibits excellent linearity over 3 orders of magnitude. The method achieved a lower limit of quantification (LLOQ) of 0.10 ng/mL using only 50 μL of plasma, with precision (RSD ≤ 8.83 %) and accuracy (88.4-102.2 %) within acceptable limits. The method was applied to determine the plasma concentration of hetrombopag in eight male beagle dogs after each administration of three 2.5 mg hetrombopag tablets. The analytical methodology described in the present work should be useful in the future work aiming to establish a model relating metal-sensitive other compounds.

01 Sep 2025·AMERICAN JOURNAL OF HEMATOLOGY

Efficacy and Safety of Hetrombopag Versus Thrombopoietin in Promoting Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Multicenter, Randomized Controlled Clinical Trial

Article

Author: Chen, Ting ; Zhao, Lu ; Wang, Dan ; Feng, Yimei ; Wang, Lu ; Ma, Liangliang ; Xing, Hongyun ; Deng, Jianchuan ; Zhu, Lidan ; Wang, Xiaoning ; Wang, Sanbin ; Yao, Han ; Wang, Xiaoqi ; Gao, Lei ; Zhang, Xi ; Liu, Huanfeng ; He, Pengcheng ; Yi, Hai ; Ren, Mingqiang ; Liu, Jia ; Wang, Linhui ; Tang, Shuhan ; Liu, Yuqing ; Lang, Tao ; Li, Li ; Gao, Shichun ; Kong, Peiyan ; Wang, Jishi ; Lou, Shifeng

ABSTRACT:

Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is pivotal for hematological malignancies but faces challenges in delayed platelet engraftment, poor graft function (PGF), and bleeding risks. Hetrombopag, a thrombopoietin receptor agonist, was evaluated to enhance platelet recovery posttransplant. Patients undergoing allo‐HSCT were randomized on Day 3 Post‐Infusion into low‐dose (2.5 mg/day), high‐dose (5 mg/day) hetrombopag groups, or a control group receiving thrombopoietin (300 U/kg/day). Endpoints included platelet/neutrophil engraftment time, PGF incidence, transfusion needs, and safety. Among 212 analyzed patients, platelet engraftment was faster in hetrombopag groups (median 13 days) versus controls (15 days; p = 0.0022), with no dose‐dependent difference (p = 0.0593). Neutrophil engraftment was also accelerated (13 vs. 15 days; p = 0.0001). PGF incidence was lower in hetrombopag groups (5.04%) versus controls (13.7%; p = 0.027). The experimental group required fewer platelet transfusions (p = 0.002), had reduced gastrointestinal bleeding, and lower costs. Secondary platelet recovery failure showed no intergroup differences. Hetrombopag safely accelerates platelet and neutrophil engraftment, reduces PGF risk, and decreases transfusion dependency post‐allo‐HSCT. Low‐dose hetrombopag demonstrated efficacy equivalent to high‐dose, offering a cost‐effective strategy to improve transplant outcomes.Trial Registration: ChiCTR2200057764.

News (Medical) associated with Herombopag Olamine

20 Oct 2025

·www.prnewswire.com

Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power

BERLIN, Oct. 20, 2025 /PRNewswire/ -- From October 17 to 21, the European Society for Medical Oncology (ESMO) Annual Congress convened in Berlin, bringing together global leaders in oncology and pharmaceutical innovation. Representing China's advancing biopharmaceutical landscape, Hengrui Pharma not only returned with a comprehensive portfolio of oncology research but also debuted as an exhibitor, marking a new milestone in its global academic engagement. Since 2016, Hengrui has presented pioneering research at the ESMO Annual Congress for ten consecutive years. This year, the company unveiled 46 studies across 14 innovative therapeutic programs, including nine oral presentations, two mini oral sessions, and four late-breaking abstracts (LBAs), underscoring its global R&D strength. These data highlight the company's commitment to multi-cancer coverage and multi-mechanism innovation in oncology. In parallel, Hengrui scheduled a series of academic events, fostering in-depth dialogue with leading global experts and clinical researchers on cutting-edge topics in oncology. These initiatives established a dynamic platform for international academic exchange and infused Chinese innovation into the global landscape of cancer diagnosis and treatment – marking a new chapter in Hengrui's journey of international scientific engagement. As one of the world's premier oncology platforms, the ESMO Annual Congress attracts more than ten thousand experts and hundreds of leading international pharmaceutical companies each year. The meeting showcases the latest advances in cancer research and therapeutics, serving as a high-level hub for academic exchange and collaboration. It continues to catalyze innovation and clinical translation across the oncology community, aligning with the 2025 Congress vision: "Standing by those who care about cancer." Global Vision: China Innovation Going Global At the ESMO 2025 Annual Congress, Hengrui co-hosted the roundtable "China Innovation Going Global," bringing together leading Chinese and international experts to discuss strategic pathways and future prospects for the globalization of China-origin innovations. During the global launch of the CARES-009 study, featuring Hengrui's innovative therapeutic combination of camrelizumab and rivoceranib, Academician Jia Fan of the Chinese Academy of Sciences and Professor Jian Zhou of Zhongshan Hospital, Fudan University, jointly presented the latest global data from the study, garnering widespread attention from the international oncology community. Ms. Jo Feng, President and Chief Operating Officer of Hengrui Pharma, led the company's delegation at this year's Congress. She stated, "ESMO serves as a premier global platform for oncology exchange, and this year, Hengrui proudly presented 46 research achievements – highlighting our growing academic presence on the world stage. As an innovation-driven global pharmaceutical company, Hengrui places medical innovation at the heart of its strategic vision, with a steadfast commitment to addressing unmet clinical needs. Looking ahead, we remain firmly patient-centric, continuing to advance groundbreaking therapies to improve the lives of patients worldwide." Breakthroughs Across Multiple Cancer Types At this year's ESMO Annual Congress, Hengrui had 46 oncology research projects accepted, including four LBAs, spanning 14 innovative therapeutic programs. Among these, nine were selected for oral presentations, two for mini oral sessions, 32 as posters, and three as e-posters. Collectively, these studies encompass more than 10 cancer types, including esophagogastric cancer, gynecologic malignancies, liver cancer, breast cancer, pancreatic cancer, lung cancer, sarcoma, biliary tract cancer, head and neck squamous cell carcinoma, prostate cancer, and thyroid cancer. In breast cancer, Hengrui had 11 research studies accepted, comprising one oral presentation, one mini oral, eight posters, and one e-poster. Notably, an LBA featuring Hengrui's antibody-drug conjugate (ADC) trastuzumab rezetecan (SHR-A1811) compared with pyrotinib plus capecitabine for patients with HER2-positive advanced or metastatic breast cancer was selected for presentation. Multiple studies highlighting both established and emerging therapies, including pyrotinib, dalpiciclib, and adebrelimab, demonstrate Hengrui's deep and sustained commitment to advancing breast cancer research. In gastrointestinal cancers, 14 studies were accepted, including two oral presentations, 11 posters, and one e-poster. Alongside flagship therapies such as camrelizumab and rivoceranib, four studies on adebrelimab in the gastrointestinal field were featured. In addition, investigational agents including HRS-4642 (a KRAS G12D inhibitor) and SHR-1701 (a PD-L1/TGF-β bifunctional antibody) were also presented, reflecting the strong momentum of both Hengrui's established portfolio and emerging pipeline in advancing care for patients with gastrointestinal malignancies. In lung cancer, six poster presentations featuring camrelizumab and adebrelimab were accepted, underscoring Hengrui's expanding footprint in this therapeutic area. These studies covered both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), further validating the clinical potential and versatility of these regimens. Across additional disease areas, including gynecologic tumors, thymic epithelial tumors, head and neck squamous cell carcinoma, sarcoma, prostate cancer, and thyroid cancer, Hengrui had 13 studies accepted, featuring a diverse range of innovative therapies such as camrelizumab, fuzuloparib, rivoceranib, rezvilutamide, adebrelimab, famitinib, HRS-7058, and HRS-4642. These included six oral presentations, one mini oral, five posters, and one e-poster, highlighting Hengrui's robust and broad-based R&D capabilities. In addition, two posters were accepted on hetrombopag and ondansetron oral soluble films, focusing on the prevention and management of chemotherapy-induced thrombocytopenia, nausea, and vomiting. Dr. Frank Jiang, Executive Vice President and Chief Strategy Officer of Hengrui Pharma, stated: "At this year's ESMO Annual Congress, we unveiled a broader and more impactful portfolio of research findings. The concentrated release of these breakthrough data not only reflects Hengrui's robust R&D capabilities, but also highlights the results of our science-driven, globally oriented innovation R&D strategy. Our pipeline is both deep and forward-looking – while reinforcing our existing product portfolio, we are also actively expanding into cutting-edge therapeutic areas. We firmly believe that through this in-depth engagement with the global oncology community, we can better enable our breakthroughs to benefit more patients worldwide." A Decade of ESMO Participation: China Innovation Going Global Since 2016, Hengrui Oncology has participated in the ESMO Annual Congress for 10 consecutive years, consistently setting new benchmarks for Chinese pharmaceutical companies. Between 2023 and 2025, Hengrui presented a total of 119 research achievements: 2023: 36 studies accepted, including two preferred oral presentations, six mini oral presentations, and 28 posters, covering multiple therapeutic areas such as gastrointestinal cancers, breast cancer, cervical cancer, pancreatic cancer, and melanoma. 2024: 37 studies accepted, spanning 13 innovative therapies and more than 10 cancer types, including esophagogastric cancer, gynecologic malignancies, liver cancer, breast cancer, and lung cancer. 2025: Marking its first-ever exhibition booth at ESMO, Hengrui presented 46 studies across 14 innovative medicines. This milestone represents a significant step forward in Hengrui's internationalization strategy and its commitment to advancing global cancer care. Commitment to Global Impact with the Promise of Patient Focus Hengrui remains steadfast in its commitment to science and innovation driven by the goal of addressing unmet patient needs. Leveraging a global R&D network, the company is advancing innovative medicines onto the international stage. Through a strategically structured pipeline, continuous breakthroughs across multiple cancer types, and active participation in global academic exchange, Hengrui Oncology is accelerating the internationalization and bringing new hope and broader treatment options to patients worldwide. About Hengrui Pharma Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Founded in 1970 with the core principle of putting patients first, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. About Hengrui Oncology Hengrui Oncology specializes in the development, production, and global commercialization of innovative cancer therapies. It is the first business unit within Hengrui to achieve technological breakthroughs and successfully enter international markets. Hengrui Oncology has established a robust and diversified oncology pipeline encompassing multiple tumor types, with a comprehensive portfolio that includes immunotherapies, targeted therapies, and ADCs. In key areas such as breast cancer, Hengrui Oncology provides full-course treatment solutions that span multiple lines of therapy. To date, 14 novel oncology agents developed by Hengrui have been approved for marketing in China. SOURCE Hengrui Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ASCOImmunotherapyDrug Approval

08 Jan 2024

·synapse.patsnap.com

TPO receptor agonists: What They Are and How to Stay Updated on the Latest Research

The TPO receptor, also known as the thrombopoietin receptor, plays a crucial role in the human body's production of platelets. Thrombopoietin, a hormone produced in the liver and kidneys, binds to the TPO receptor, stimulating the production and maturation of megakaryocytes, which are the precursor cells of platelets. This interaction is essential for maintaining adequate platelet levels in the blood, which are vital for normal blood clotting and preventing excessive bleeding. Understanding the TPO receptor's function has led to the development of drugs that target this receptor, offering potential therapeutic options for conditions associated with low platelet counts, such as immune thrombocytopenia and chemotherapy-induced thrombocytopenia. The analysis of the target TPO receptor reveals a competitive landscape with multiple companies actively involved in research and development. The highest stage of development is the "Approved" phase, with several companies having drugs in this phase. Thrombocytopenia and Purpura, Thrombocytopenic, Idiopathic are the most common indications for drugs under this target. Small molecule drugs, Fusion proteins, and Biosimilars are progressing most rapidly, indicating intense competition. China, the United States, the European Union, and Japan are the leading countries in terms of development under this target. Further analysis is required to understand the specific R&D progress of each company, the research institutions involved in biosimilar development, and the factors contributing to the progress in China. How do they work?TPO receptor agonists are a type of medication that act on the thrombopoietin (TPO) receptor in the body. Thrombopoietin is a hormone that regulates the production of platelets, which are essential for blood clotting. TPO receptor agonists mimic the action of thrombopoietin and stimulate the production of platelets in the bone marrow. From a biomedical perspective, TPO receptor agonists are used in the treatment of certain medical conditions that result in low platelet counts, such as immune thrombocytopenia (ITP) and chemotherapy-induced thrombocytopenia. By increasing platelet production, these medications help prevent bleeding episodes and improve overall blood clotting function. TPO receptor agonists can be administered orally or through injection, depending on the specific drug. They work by binding to the TPO receptor on the surface of bone marrow cells, which triggers a signaling cascade leading to increased platelet production. These medications are typically used when other treatments, such as corticosteroids, have been ineffective or are not suitable for the patient. It is important to note that TPO receptor agonists may have potential side effects, such as headache, nausea, fatigue, and muscle pain. Close monitoring of platelet counts and regular follow-up with a healthcare professional are necessary during treatment with these medications to ensure optimal effectiveness and safety. List of TPO receptor AgonistsThe currently marketed TPO receptor agonists include: Herombopag OlamineLusutrombopagAvatrombopag MaleateEltrombopag DiolamineRomiplostimRecombinant human thrombopoietin(Shenyang Sunshine Pharmaceutical)Eltrombopag cholineNIP-022NIP-022SCB-219MFor more information, please click on the image below. What are TPO receptor agonists used for?TPO receptor agonists are used in the treatment of certain medical conditions that result in low platelet counts, such as immune thrombocytopenia (ITP) and chemotherapy-induced thrombocytopenia. For more information, please click on the image below to log in and search. How to obtain the latest development progress of TPO receptor agonists?In the Synapse database, you can keep abreast of the latest research and development advances of TPO receptor agonists anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

100 Deals associated with Herombopag Olamine

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	B02BX	DB16184

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anemia, Aplastic	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	16 Jun 2021
Chronic thrombocytopenia	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	16 Jun 2021
Purpura, Thrombocytopenic, Idiopathic	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	16 Jun 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic liver disease	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	31 Jul 2024
Thrombocytopenia	Phase 3	United States	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	11 Jan 2022
Thrombocytopenia	Phase 3	Australia	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	11 Jan 2022
Thrombocytopenia	Phase 3	Europe	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	11 Jan 2022
Bladder Cancer	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Nov 2019
Breast Cancer	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Nov 2019
Lymphoma	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Nov 2019
Non-Small Cell Lung Cancer	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Nov 2019
Pancreatic Cancer	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Nov 2019
Solid tumor	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Nov 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ChiCTR2300068232 (ASH2025)	Phase 2	-	43	Hetrombopag 15 mg/day	jpmbmfzptb(alzpzltzfd) = infection being the most frequent (5 patients, 11.6%) tckygtlkpr (ugoaepsyua )	Positive	06 Dec 2025
ASH2025	Not Applicable	Purpura, Thrombocytopenic, Idiopathic	34	Hetrombopag (Acute ITP group)	nigrllnsnx(erbeewdjqj) = 1 patient rcxeznudeu (mzbzvgzuyy ) View more	Positive	06 Dec 2025
				Hetrombopag (Persistent ITP group)
ASH2025	Not Applicable	Refractory Severe Aplastic Anemia	32	IST plus Hetrombopag	zsvugxprjz(jvmcayxmfr) = zgjcxqjavb vnxjspvdkx (nprwglwdrx ) View more	Positive	06 Dec 2025
				ATG+CsA alone	zsvugxprjz(jvmcayxmfr) = dhmeagangh vnxjspvdkx (nprwglwdrx ) View more
ASH2025	Not Applicable	Purpura, Thrombocytopenic, Idiopathic	167	Hetrombopag	nztvjntxjv(graxquoqol) = qchtspwqoz uorbwuybrd (bavnewybsi ) View more	Positive	06 Dec 2025
				Hetrombopag (Newly diagnosed ITP)	nztvjntxjv(graxquoqol) = nsasslxtdt uorbwuybrd (bavnewybsi ) View more
NCT05864014 (ASH2025)	Phase 3	Advanced Malignant Solid Neoplasm	213	Hetrombopag	oidhwsihpz(qdilbgkcnq) = vugupcbmsx ftggkrywba (anwiilzdmp ) View more	Positive	06 Dec 2025
				Hetrombopag administered only prior to the initiation of the first chemotherapy cycle [C1], with subsequent switch to placebo	oidhwsihpz(qdilbgkcnq) = bixselhoan ftggkrywba (anwiilzdmp ) View more
NCT05333861 (ASH2025)	Not Applicable	Purpura, Thrombocytopenic, Idiopathic	334	Hetrombopag (Primary Immune Thrombocytopenia)	osbxutvbyg(pqxjjgnapd) = no unexpected AEs were observed dyxkyvbgxf (vigidiwdbk )	Positive	06 Dec 2025
NCT04737850 (ASH2025)	Phase 3	Purpura, Thrombocytopenic, Idiopathic	88	Hetrombopag	zsokzljbdo(fkskyzfokg) = jqlzsldfbi kyftvunorp (hdvrqaygkv ) View more	Positive	06 Dec 2025
				Placebo	zsokzljbdo(fkskyzfokg) = fguguiafrj kyftvunorp (hdvrqaygkv ) View more
NCT03222843 (HETROM-2.5, ASH2025)	Phase 3	Purpura, Thrombocytopenic, Idiopathic	80	Hetrombopag 2.5 mg	plrtlcwxbz(rmgoimakuc) = eqrpwivkii bejyfsjidn (dnpnlwxgme )	Positive	06 Dec 2025
				Hetrombopag 5.0 mg	plrtlcwxbz(rmgoimakuc) = vktmfbwtws bejyfsjidn (dnpnlwxgme )
NCT06562738 (ASH2025)	Phase 4	Thrombocytopenia	42	Hetrombopag 7.5 mg	flfofuuafe(sfhbcbpfbh) = xsitzvjygf wnueleexeo (shgwzdybar )	Positive	06 Dec 2025
NCT05394285 (ESMO2025)	Phase 4	-	60	Hetrombopag 7.5 mg daily	jsnvnikemc(ilpfhghgco) = No treatment-emergent severe adverse events occurred. pzwpoasxsa (hoogahwbjc )	Positive	17 Oct 2025
				Recombinant human thrombopoietin (rhTPO) 15000 U daily

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis